Note to our followers: Due to a lack of sufficient funding, HealthNewsReview.org will cease daily publication of new content at the end of 2018. Publisher Gary Schwitzer and other contributors may post new articles periodically. If you wish to donate, your gift might help keep the site available to the public for a few more years, by defraying costs of web hosting and maintenance. All of our 6,000+ published articles contain lessons to help people improve their critical thinking about health care. Read more about our change in status. And here's how to make a donation.

Categories

Tags

Our Review Summary

The release focuses on a recent “proof-in-principle” study that found it is feasible to use at-home testing kits to screen low income women with limited access to medical care for human papillomavirus (HPV) infection, which can lead to cervical cancer. The release could do more to clarify the sensitivity and specificity of the screening tools, but does a good job of making clear that more work needs to be done before this approach could be deployed on a broad scale.

Why This Matters

As the National Cancer Institute notes, virtually all cervical cancers are caused by HPV — with most of them being caused by certain strains of HPV. And early diagnosis of HPV infection can help to prevent cancers, or allow patients and healthcare providers the warning they need to monitor for cervical cancer. That makes screening for HPV important, and especially so for patients with limited resources who may not have regular access to healthcare providers for screening or regular check-ups. And those at-risk communities are precisely who this study was trying to address. It’s important to make clear — as this release does — that cost remains a challenge, and that regulatory barriers remain. Most importantly, the release stresses that more work needs to be done before this approach to screening moves from theoretical to practical.

Criteria

Satisfactory

The release does not place a pricetag on HPV screening — which would include the test kit, analysis and follow-up clinical visit. However, the release does explicitly say that “there is more work to be done, such as identifying ways to make the self-collection process more efficient and cost-effective.” That acknowledgment is enough to earn it a satisfactory rating here.

Satisfactory

This is a tricky question, as it is not clear how one should define the relevant benefit. The paper itself defines the goal of the study as evaluating the “validity and acceptability” of at-home self-collection of samples for HPV screening. If part of assessing “acceptability” was determining whether mailing self-collection kits improved screening rates, should the benefit be defined as successfully submitting a sample for screening? If so, the release failed, since it doesn’t even tell readers how many women received screening tests through the mail (284 women, according to the related paper). However, validity is easier to address. How well did the at-home, self-collected samples compare to other screening tests? The release does address this head on. It states that the at-home, self-collected test indicated 12.4% of women had high-risk HPV infections. In-clinic, self-collected tests indicated 15.5% had high-risk HPV infections. And clinician-collected tests indicated 11.4% of women had high-risk HPV infections. Those are hard numbers, and we’ll give the release the benefit of the doubt on this one. However, those three different numbers raise some questions, which the release doesn’t do a good job of addressing. More on that below.

Not Satisfactory

The release did not address two key potential harms, namely the failure to identify someone who has high-risk HPV, and the “false positive” misdiagnosis of people who did not have high-risk HPV. This is the difference between “sensitivity” and “specificity.” It’s particularly relevant in this instance because HPV screening has a track record of problems with both specificity and sensitivity— and because the release itself makes clear that there were people diagnosed as at high risk in some of the screening tests, but not others. Missing someone who is at high risk is clearly problematic. But being told that one faces significant medical risks that one does not actually face can also have ramifications for future healthcare, with consequences both physical and financial.

Another potential harm could be having a certain rate of patients sending in the test but not following up, leaving clinicians with positive tests and patients lost to follow up which would skew the impact of the screening effort.

Not Satisfactory

This boils down to a very simple problem: the release gives readers key information and then fails to explain it. This concern is in regard to the lack of comparison in screening results across three types of tests: at-home, self-collected tests indicated 12.4% of women had high-risk HPV infections; in-clinic, self-collected tests indicated 15.5% had high-risk HPV infections; and clinician-collected tests indicated 11.4% of women had high-risk HPV infection.

To most readers, the difference between 11.4% and 15.5% seems like a lot — more than 4%. If they were to do the math at home, they’d see that eight people (out of 193) were diagnosed as being at high risk in one scenario, but not in another. What gives? But the release only addresses this with a quote saying “We found comparable detection between self-collection and physician-collection.” That’s not helpful. In addition, the release refers more than once to the fact that “all women found to have high-grade cervical lesions…were positive for high-risk HPV in their home self-collected sample.” But the release doesn’t tell them that this group consisted of fewer than 10 people, or the extent to which that may be extrapolated to a larger population. In short, it’s important to address sensitivity and specificity when writing about a diagnostic tool.

Satisfactory

HPV — particularly certain strains of HPV — can significantly increase risk for cervical cancer. There’s no doubt about that. However, not all women who contract HPV will get cervical cancer. There’s no doubt about that either. In fact, the CDC notes that 80 percent of women have contracted HPV by the time they are 50, yet the National Cancer Institute estimates that less than one percent of women will contract cervical cancer in their lifetime. It can be difficult to highlight the importance of HPV screening without edging into “disease mongering” territory. This release walks up to the line, but doesn’t cross it.

Satisfactory

The release includes information about not only sources of funding, but also sources of research equipment — which is really good to see. The release also includes clear information regarding potential conflicts of interest.

Comments

We Welcome Comments. But please note: We will delete comments left by anyone who doesn’t leave an actual first and last name and an actual email address.

We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, or profanity. We will also end any thread of repetitive comments. Comments should primarily discuss the quality (or lack thereof) in journalism or other media messages about health and medicine. This is not intended to be a forum for definitive discussions about medicine or science. Nor is it a forum to share your personal story about a disease or treatment -- your comment must relate to media messages about health care. If your comment doesn't adhere to these policies, we won't post it. Questions? Please see more on our comments policy.

Current ye@r *

Leave this field empty

Our Comments Policy

We welcome comments, which users can leave at the end of any of our systematic story reviews or at the end of any of our blog posts.

But before leaving a comment, please review these notes about our policy.

You are responsible for any comments you leave on this site.

This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.

We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.

We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.

“Shed light, not just heat. Facts, challenges, disagreements, corrections — those are all fine. Attacking the person, instead of the idea or the interpretation, is neither acceptable nor helpful.”

We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.

And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.

The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.

News Release Reviews

Newsletter

Get caught up with this once-a-week email

We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.

Newsletter Signup

Sign up for HealthNewsReview.org weekly email digest

Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.-Gary Schwitzer, Publisher, HealthNewsReview.org

Email Address*

First Name*

Last Name

Please verify

Email

This field is for validation purposes and should be left unchanged.

By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)

Tags

Newsletter Signup

Get caught up with this once-a-week email

We will not display your name or e-mail address on the site, nor will we share your e-mail address with any third parties.

Newsletter Signup

Sign up for HealthNewsReview.org weekly email digest

Thank you for joining the HealthNewsReview.org mailing list. It’s a good way for you to stay up-to-date on what we’ve published, even if you forget to come to our website every day or every week.-Gary Schwitzer, Publisher, HealthNewsReview.org

Email Address*

First Name*

Last Name

Please verify

Name

This field is for validation purposes and should be left unchanged.

By submitting this form, you are granting: HealthNewsReview.org, University of Minnesota , Minneapolis, MN, 55455, United States, https://www.healthnewsreview.org permission to email you. You may unsubscribe via the link found at the bottom of every email. Emails are serviced by Mailchimp. (See their Email Privacy Policy for details.)